Jump to content
IndiaDivine.org

scripps conference

Rate this topic


Guest guest

Recommended Posts

I just gave my presentation at scripps about therapeutic drug herb interaction.

While the

talk was well received in general, as I predicted, the chinese research was

unanimously

dismissed as so flawed as to be worthless. I presented some of the better

studies from

the BP website on diabetes. They had controlled matching groups and outcome

criteria.

However there were major flaws in each of the studies from a general

perpsective. No

long term followup. Using diverse treatment groups and then only doing an

analysis of

median values with no details. But this biggest objection of all is one we can

never get

around. It is not accepted that massive polypharmacy studies are valid. So the

mere fact

of having a 15 herb formula being studied invalidates the study from the get go.

Especially if the study allows, as most of the ones I cited do, the prescriber

to add herbs to

a base formula for a wide range of varying presentations and then fail to

account for these

variables in the final analysis.

 

It was a cogent and cutting crititque. While I anticipated it, there was no

defense I could

offer short of some science fiction about advanced computer modeling. This

experience is

crystallizing a trend in my thoughts over the past year. There is absolutely no

interest

amongst mainstream researchers in what we actually do. We have failed to prove

the

validity of our model and now it may be too late. Research in supplements is

pressing full

steam ahead, but it does not include much TCM and I suspect much less in the

future.

The emphasis is clear. It will be on single substances and not formulas. Each

herb in a

formula will need to be proven safe and effective ALONE before they are ever

combined for

valid research. That is their attitude and I don't expect it to change. This

is why I have

been saying for years that unless we FIRST prove that pattern differentiation is

real and we

have inter-rater reliability, nothing else we do will matter. Any positive

study can be easily

dismissed if the assessment criteria have not first been validated. Bob Felt

has also made

that point here and elsewhere in print for over a decade. Sadly,the advice fell

on deaf

ears. We are on our own, as we always have been and likely always will be.

 

Link to comment
Share on other sites

At 1:04 AM +0000 1/8/05, wrote:

>We have failed to prove the

>validity of our model and now it may be too late. Research in

>supplements is pressing full steam ahead, but it does not include

>much TCM and I suspect much less in the future. The emphasis is

>clear. It will be on single substances and not formulas. Each herb

>in a formula will need to be proven safe and effective ALONE before

>they are ever combined for valid research. That is their attitude

>and I don't expect it to change. This is why I have been saying for

>years that unless we FIRST prove that pattern differentiation is

>real and we have inter-rater reliability, nothing else we do will

>matter. Any positive study can be easily dismissed if the

>assessment criteria have not first been validated.

--

 

 

 

Thanks for your description of your experience at this conference.

You seem to be somewhat disappointed by it, but I have to say I am

not (but then I didn't have to suffer as you did). These researchers

are not interested in what we do, and are heavily biased in their

approach to what is medicine.

 

What these researchers seem to be saying is that medicine should be

defined by their research methods, and if something doesn't fit their

methodology then it isn't medicine. Clearly such a position is

nonsense, and reflects only their bias as researchers per se, and

researchers in pursuit of pharmaceuticals in particular.

 

There is nothing we can prove to these people. What we need to do is

formulate our own ways to validate what we do, and speak up for that.

As you say, we may have done a poor job so far. Nonetheless, how

difficult would it be to replicate one of the diabetes studies you

refer to, with added follow up? (btw, it would be interesting if you

were to post more detailed critiques of these diabetes studies you

presented; I agree with you that we all need to learn as much as we

can about doing good research in our field)

 

In my view we do not need to prove pattern differentiation is " real " .

I don't even know what that means. If we can show to our satisfaction

that treatment based on pattern differentiation is effective, why is

that not sufficient to our needs, and the needs of our patients.

 

Even if we were able to prove to their satisfaction that pattern

diagnosis was valid, these researchers would still not be interested

in what we do. They would still want to reduce the research to single

substances. They are probably incapable of thinking outside that

frame of reference. That's their limitation, not ours.

 

Rory

--

 

 

 

Link to comment
Share on other sites

Todd

Dont be dishearten. Change takes time and seeds once planted may sprout in time.

It is important to keep having a presence. I been there and can sympathize

alon

 

 

Link to comment
Share on other sites

thanks for going as well as presenting your findings to us here.

 

The validation of TCM can not be allowed to rest with WM period.

 

course the Qi,

Ed Kasper LAc Santa Cruz, CA.

Link to comment
Share on other sites

 

This reminds me of my own experiences lecturing at various

institutions over the years. One that comes to mind was only a block

away from the Scripps seminar site, at Novartis Institute. It is a

huge operation, backed by hundreds of millions of dollars investment in

the building and equipment alone. I was contacted by a woman who was a

major researcher there, who had just returned from researching

potential drugs from Chinese medicinals in Yunnan province.

I made my case to the cream of young research scientists for the

place of polypharmacy, but their questions came down to the same narrow

interest. What herb could have its active constituents isolated in

vitro in order to develop new drugs for cancer and other diseases?

Novartis at that point (five years ago) had equipment that could

analyze 10,000 substances at the same time, looking for new drugs.

Interestingly, since then Novartis has moved to the forefront of

what is called 'combinatorial chemistry' under the direction of Peter

Schulz, who believes that the future of medicine is in combinations of

drugs, not in single drugs, i.e. polypharmacy. While this approach is

different then the combination of crude medicinals in prescriptions as

in Chinese medicine, it is based on a similar idea of matching the

body's complexity with a complex of medical substances. Add to this

the work being done at the Institute for Systems Biology, and perhaps

the future isn't so bleak.

For years, I thought it might be possible to be an herbal

consultant to the pharmaceutical industry, as we have lots of research

into natural products being done in San Diego, in such places as

Novartis and Scripps Institute of Oceanography. The Chinese have

accumulated a huge database of natural medicines, with accompanying

pharmaceutical data, and it is a shame that this 'treasure chest' is

largely being ignored. I met with one drug company group based in

Ithaca, N.Y. a few years back who were trying to 'patent' a group of

polypharmacy Chinese extracts for cancer treatment as well. None of my

inquiries were ever followed up upon (perhaps it was my beard?). I

needed to learn that scientists, researchers and entrepreneurs have

their own clubs, which are almost impossible to join without the

correct credentials. No one cares about an herbal medicine professor

and private practitioner in these clubs, no matter how much experience

one may have.

 

 

 

On Jan 7, 2005, at 5:04 PM, wrote:

 

>

> I just gave my presentation at scripps about therapeutic drug herb

> interaction.  While the

> talk was well received in general, as I predicted, the chinese

> research was unanimously

> dismissed as so flawed as to be worthless.  I presented some of the

> better studies from

> the BP website on diabetes.  They had controlled matching groups and

> outcome criteria. 

> However there were major flaws in each of the studies from a general

> perpsective.  No

> long term followup.  Using diverse treatment groups and then only

> doing an analysis of

> median values with no details.  But this biggest objection of all is

> one we can never get

> around.  It is not accepted that massive polypharmacy studies are

> valid.  So the mere fact

> of having a 15 herb formula being studied invalidates the study from

> the get go. 

> Especially if the study allows, as most of the ones I cited do, the

> prescriber to add herbs to

> a base formula for a wide range of varying presentations and then

> fail to account for these

> variables in the final analysis.

>

> It was a cogent and cutting crititque.  While I anticipated it, there

> was no defense I could

> offer short of some science fiction about advanced computer

> modeling.  This experience is

> crystallizing a trend in my thoughts over the past year.  There is

> absolutely no interest

> amongst mainstream researchers in what we actually do.  We have

> failed to prove the

> validity of our model and now it may be too late.  Research in

> supplements is pressing full

> steam ahead, but it does not include much TCM and I suspect much less

> in the future. 

> The emphasis is clear.  It will be on single substances and not

> formulas.  Each herb in a

> formula will need to be proven safe and effective ALONE before they

> are ever combined for

> valid research.  That is their attitude and I don't expect it to

> change.  This is why I have

> been saying for years that unless we FIRST prove that pattern

> differentiation is real and we

> have inter-rater reliability, nothing else we do will matter.  Any

> positive study can be easily

> dismissed if the assessment criteria have not first been validated. 

> Bob Felt has also made

> that point here and elsewhere in print for over a decade.  Sadly,the

> advice fell on deaf

> ears.  We are on our own, as we always have been and likely always

> will be.

>

> Todd

 

 

 

Link to comment
Share on other sites

I am actually surprised at your description of this year's response,

because last year I had some positive interactions with people at the

Scripps conference. A couple of the presenters (last year) who were

M.D.'s were very sympathetic to Chinese medicine, and one of the

presenters had taken two workshops on Chinese herbal medicine with me

in San Francisco. Another M.D. was in a partnership with a Chinese

medicine practitioner in Albuquerque, N.M.

 

 

 

 

On Jan 8, 2005, at 2:48 PM, alon marcus wrote:

 

 

> Dont be dishearten. Change takes time and seeds once planted may

> sprout in time. It is important to keep having a presence. I been

> there and can sympathize

> alon

>

>

 

 

 

 

Link to comment
Share on other sites

" I made my case to the cream of young research scientists for the

place of polypharmacy, but their questions came down to the same

narrow interest. What herb could have its active constituents isolated

in vitro in order to develop new drugs for cancer and other diseases?

Novartis at that point (five years ago) had equipment that could

analyze 10,000 substances at the same time, looking for new drugs. "

 

Z'ev's posting gives credence to the point of view of " critical

medical anthropology (CMA), " one of the main schools of contemporary

medical anthropology. This school is heavily influenced by Marxism in

terms of its class reading of social and system dynamics. It is the

CMA folks who gave us the term " biomedical hegemony. " According to

CMAists, biomedicine is an outgrowth of and inextricably entwined with

capitalism, including its research methodology which is designed to

discover/create medicines to increase personal and corporate wealth.

 

From this point of view, we, as proponents of CM, are engaged in a

" class struggle " over resources in the marketplace, and we are heavily

outgunned, i.e., undercapitalized. The goods news, according to CMA

theory, is that all complex societies by their nature allow for

medical pluralism one way or another. So perhaps the issue is simply

carving out a viable niche and recognizing that that's the best we can

do. From that point of view, perhaps we should only be concerned with

getting our own house in order -- whatever that may mean.

 

As an unabashed capitalist myself, it's basic business 101 to identify

a currently unmet or undermet need, come up with a product that fills

that need, then let consumers with that need know you have a solution

to their want. Price that solution at the correct point and provide

that solution in an acceptable way to the niche you are marketing to.

 

Just thinking out loud here.

 

Bob

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...